Ingrid Meinl1, Joachim Havla1, Reinhard Hohlfeld2, Tania Kümpfel1. 1. Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany. 2. Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany/The Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Abstract
BACKGROUND: Fingolimod is an effective treatment for active relapsing-remitting multiple sclerosis (MS). Discontinuation of therapy may be followed by recurrence of disease activity. Thus, female MS patients may be at risk of relapse during pregnancy after stopping fingolimod. OBJECTIVES AND METHODS: To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy. RESULTS: All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod. CONCLUSION: The risk of recurrence of disease activity during pregnancy after stopping fingolimod may be substantial. This should be considered and discussed with MS patients who are planning to become pregnant.
BACKGROUND:Fingolimod is an effective treatment for active relapsing-remitting multiple sclerosis (MS). Discontinuation of therapy may be followed by recurrence of disease activity. Thus, female MSpatients may be at risk of relapse during pregnancy after stopping fingolimod. OBJECTIVES AND METHODS: To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy. RESULTS: All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod. CONCLUSION: The risk of recurrence of disease activity during pregnancy after stopping fingolimod may be substantial. This should be considered and discussed with MSpatients who are planning to become pregnant.
Entities:
Keywords:
Fingolimod; multiple sclerosis; pregnancy; recurrence of disease activity
Authors: Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer Journal: Drug Saf Date: 2019-05 Impact factor: 5.606
Authors: Wei Zhen Yeh; Putu Ayu Widyastuti; Anneke Van der Walt; Jim Stankovich; Eva Havrdova; Dana Horakova; Karolina Vodehnalova; Serkan Ozakbas; Sara Eichau; Pierre Duquette; Tomas Kalincik; Francesco Patti; Cavit Boz; Murat Terzi; Bassem I Yamout; Jeannette Lechner-Scott; Patrizia Sola; Olga G Skibina; Michael Barnett; Marco Onofrj; Maria José Sá; Pamela Ann McCombe; Pierre Grammond; Radek Ampapa; Francois Grand'Maison; Roberto Bergamaschi; Daniele L A Spitaleri; Vincent Van Pesch; Elisabetta Cartechini; Suzanne Hodgkinson; Aysun Soysal; Albert Saiz; Melissa Gresle; Tomas Uher; Davide Maimone; Recai Turkoglu; Raymond Mm Hupperts; Maria Pia Amato; Franco Granella; Celia Oreja-Guevara; Ayse Altintas; Richard A Macdonell; Tamara Castillo-Trivino; Helmut Butzkueven; Raed Alroughani; Vilija G Jokubaitis Journal: Neurology Date: 2021-04-20 Impact factor: 9.910
Authors: Gitanjali Das; Vincent Damotte; Jeffrey M Gelfand; Carolyn Bevan; Bruce A C Cree; Lynn Do; Ari J Green; Stephen L Hauser; Riley Bove Journal: Neurol Neuroimmunol Neuroinflamm Date: 2018-03-19